{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:28:52Z","timestamp":1760783332669},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,11,3]],"date-time":"2010-11-03T00:00:00Z","timestamp":1288742400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1007\/s10549-010-1222-3","type":"journal-article","created":{"date-parts":[[2010,11,2]],"date-time":"2010-11-02T14:40:37Z","timestamp":1288708837000},"page":"431-439","source":"Crossref","is-referenced-by-count":13,"title":["Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials"],"prefix":"10.1007","volume":"125","author":[{"given":"Joanne L.","family":"Blum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Kohles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nana","family":"Scotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Odom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Gl\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,3]]},"reference":[{"key":"1222_CR1","unstructured":"U.S. Centers for Disease Control and Prevention: Breast cancer rates by age. http:\/\/www.cdc.gov\/cancer\/breast\/statistics\/age.htm"},{"key":"1222_CR2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"598","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 598:225\u2013249","journal-title":"CA Cancer J Clin"},{"key":"1222_CR3","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1200\/JCO.2009.22.9450","volume":"27","author":"WF Anderson","year":"2009","unstructured":"Anderson WF, Jatoi I, Sherman ME (2009) Qualitative age interactions in breast cancer studies: mind the gap. J Clin Oncol 27:5308\u20135311","journal-title":"J Clin Oncol"},{"key":"1222_CR4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.1992.03490010059030","volume":"268","author":"K Christman","year":"1992","unstructured":"Christman K, Muss HB, Case LD, Stanley V (1992) Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment]. JAMA 268:57\u201362","journal-title":"JAMA"},{"key":"1222_CR5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.critrevonc.2007.12.003","volume":"66","author":"G Pentheroudakis","year":"2008","unstructured":"Pentheroudakis G, Fountzilas G, Kalofonos HP, Hellenic Cooperative Oncology Group et al (2008) Palliative chemotherapy in elderly patients with common metastatic malignancies: a Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol Hematol 66:237\u2013247","journal-title":"Crit Rev Oncol Hematol"},{"key":"1222_CR6","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1200\/JCO.2007.10.9710","volume":"25","author":"HB Muss","year":"2007","unstructured":"Muss HB, Berry DA, Cirrincione C et al (2007) Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol 25:3699\u20133704","journal-title":"J Clin Oncol"},{"issue":"3 Suppl 6","key":"1222_CR7","first-page":"105","volume":"22","author":"GW Sledge","year":"1995","unstructured":"Sledge GW, Robert N, Sparano JA et al (1995) Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. Semin Oncol 22(3 Suppl 6):105\u2013108","journal-title":"Semin Oncol"},{"key":"1222_CR8","unstructured":"Xeloda\u00ae (capecitabine) [prescribing information]: Genentech, Inc. South San Francisco, CA; 2009"},{"key":"1222_CR9","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2003.08.013","volume":"21","author":"GW Sledge","year":"2003","unstructured":"Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21:588\u2013592","journal-title":"J Clin Oncol"},{"key":"1222_CR10","doi-asserted-by":"crossref","unstructured":"Stockler M, Sourjina T, Grimison P et al (2007) A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 25:39s (18S; abstr 1031)","DOI":"10.1200\/jco.2007.25.18_suppl.1031"},{"key":"1222_CR11","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","volume":"20","author":"J O\u2019Shaughnessy","year":"2002","unstructured":"O\u2019Shaughnessy J, Miles D, Vukelja S et al (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20:2812\u20132823","journal-title":"J Clin Oncol"},{"key":"1222_CR12","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","volume":"17","author":"JL Blum","year":"1999","unstructured":"Blum JL, Jones SE, Buzdar AU et al (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17:485\u2013493","journal-title":"J Clin Oncol"},{"key":"1222_CR13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","volume":"92","author":"JL Blum","year":"2001","unstructured":"Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B (2001) Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759\u20131768","journal-title":"Cancer"},{"key":"1222_CR14","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/sj.bjc.6600261","volume":"86","author":"DC Talbot","year":"2002","unstructured":"Talbot DC, Moiseyenko V, Van Belle S et al (2002) Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic\/advanced breast cancer pretreated with anthracyclines. Br J Cancer 86:1367\u20131372","journal-title":"Br J Cancer"},{"key":"1222_CR15","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","volume":"12","author":"JA O\u2019Shaughnessy","year":"2001","unstructured":"O\u2019Shaughnessy JA, Blum J, Moiseyenko V et al (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer. Ann Oncol 12:1247\u20131254","journal-title":"Ann Oncol"},{"issue":"Suppl 2","key":"1222_CR16","first-page":"1","volume":"8","author":"L Balducci","year":"2001","unstructured":"Balducci L (2001) The geriatric cancer patient: equal benefit from equal treatment. Cancer Control 8(Suppl 2):1\u201325","journal-title":"Cancer Control"},{"key":"1222_CR17","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1001\/archinte.1996.00440080078009","volume":"156","author":"NK Ibrahim","year":"1996","unstructured":"Ibrahim NK, Frye DK, Buzdar AU, Walters RS, Hortobagyi GN (1996) Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer: tolerance and outcome. Arch Intern Med 156:882\u2013888","journal-title":"Arch Intern Med"},{"key":"1222_CR18","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa0810266","volume":"360","author":"HB Muss","year":"2009","unstructured":"Muss HB, Berry DA, Cirrincione CT et al (2009) Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 360:2055\u20132065","journal-title":"N Engl J Med"},{"key":"1222_CR19","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24816","volume":"116","author":"MF Rimawi","year":"2010","unstructured":"Rimawi MF, Shetty PB, Weiss HL, Schiff R, Osborne CK, Chamness GC, Elledge RM (2010) Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer 116:1234\u20131242","journal-title":"Cancer"},{"key":"1222_CR20","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1016\/j.ejca.2009.06.027","volume":"45","author":"F Heitz","year":"2009","unstructured":"Heitz F, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, Traut A, du Bois A (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45:2792\u20132798","journal-title":"Eur J Cancer"},{"key":"1222_CR21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/cncr.11083","volume":"97","author":"J Chang","year":"2003","unstructured":"Chang J, Clark GM, Allred DC, Mohsin S, Chamness G, Elledge RM (2003) Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 97:545\u2013553","journal-title":"Cancer"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1222-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-010-1222-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-010-1222-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T12:49:31Z","timestamp":1592052571000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-010-1222-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,3]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["1222"],"URL":"https:\/\/doi.org\/10.1007\/s10549-010-1222-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,3]]}}}